Topics

IQVIA Reports First-Quarter 2019 Results, Reaffirms Full-Year Guidance

07:00 EDT 1 May 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
First-quarter revenue $2,684 million and Adjusted EBITDA $587 million GAAP Diluted Earnings per Share $0.29; Adjusted Diluted Earnings per Share $1.53 Record constant currency or...

Other Sources for this Article

Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com)
+1.973.257.7144

Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com)
+1.484.567.6732

NEXT ARTICLE

More From BioPortfolio on "IQVIA Reports First-Quarter 2019 Results, Reaffirms Full-Year Guidance"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...